{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:44Z","timestamp":1746417764541,"version":"3.40.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Piribedil is an orally active dopamine agonist that has been widely used for Parkinson disease (PD), with its partial D2\/D3 agonistic functions and alpha2-adrenoreceptor antagonistic effects, piribedil has been proved to be efficacious in the relief of motor symptoms in PD, while it can also lead to impulse control disorders such as pathological gambling due to its dopamine agonistic effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 28-year-old Chinese female patient with Parkinson disease and a history of taking piribedil finally developed pathological gambling and depressive episode.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>After a careful clinical observation and evaluation, the patient met the criteria of severe depressive episode and pathological gambling due to antiparkinson therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We discontinued piribedil and picked bupropion, a dopamine reuptake inhibitor, to alleviate the depressive symptom. Benzhexol and selegiline were also added for the control of motor fluctuations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 3 weeks\u2019 treatment, the patient's depressive mood was significantly alleviated and her recurring PD symptoms were also relieved. She was no more addicted to network gambling, and there was no recurrence during the 1-year follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Piribedil-induced problem gambling and impulse control disorders are side effects needed to be evaluated when commencing a patient on piribedil. This case further emphasizes the importance of monitoring and controlling Parkinson symptoms after drug reduction or withdrawal. Anticipation of this risk strengthens the significance of detailed medical history-taking and targeted clinical management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024568","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T16:37:36Z","timestamp":1614011856000},"page":"e24568","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pathological gambling in a patient on piribedil"],"prefix":"10.1097","volume":"100","author":[{"given":"Yingtan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Mental Health, Jining Medical University, Jining"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Lu","sequence":"additional","affiliation":[{"name":"Peking University the Sixth Hospital (Institute of Mental Health), Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-8046","authenticated-orcid":false,"given":"Guanglei","family":"Xun","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.parkreldis.2013.02.007","article-title":"Pathological gambling in Parkinson's disease. A comprehensive review","volume":"19","author":"Santangelo","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1176\/ps.50.8.1021","article-title":"Prevalence, assessment, and treatment of pathological gambling: a review","volume":"50","author":"Petry","year":"1999","journal-title":"Psychiatr Serv"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson's disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2007.05.006","article-title":"Predictors of impulsivity and reward seeking behavior with dopamine agonists","volume":"14","author":"Ondo","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurol"},{"key":"R10-20250504","first-page":"690","article-title":"Impulse control disorders in Parkinson disease","volume":"6","author":"Weintraub","year":"2010","journal-title":"CNS Spectrums"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/WNF.0b013e3181c4ae2e","article-title":"Impulse control disorder and piribedil","volume":"33","author":"Tschopp","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-016-0360-5","article-title":"Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease","volume":"30","author":"Perez-Lloret","year":"2016","journal-title":"CNS Drugs"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1515\/med-2018-0041","article-title":"Clinical effects of piribedil in adjuvant treatment of Parkinson's disease: a meta-analysis","volume":"13","author":"Peihua","year":"2018","journal-title":"Open Med (Wars)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1002\/mds.5568","article-title":"DA agonists - non-Ergot derivatives: piribedil","volume":"17","author":"Goetz","year":"2002","journal-title":"Mov Disord"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D(2)\/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2466\/pr0.1996.78.2.635","article-title":"Pathological gambling and depression","volume":"78","author":"Becona","year":"1996","journal-title":"Psychol Rep"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1590\/S0004-282X2012000800011","article-title":"Depression in Parkinson's disease: diagnosis and treatment","volume":"70","author":"Costa","year":"2012","journal-title":"Arquivos De Neuro Psiquiatria"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/ajp.141.2.215","article-title":"Affective disorders among pathological gamblers seeking treatment","volume":"141","author":"Mccormick","year":"1984","journal-title":"Am J Psychiatry"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2105\/AJPH.88.7.1093","article-title":"Taking chances: problem gamblers and mental health disorders--results from the St. Louis Epidemiologic Catchment Area Study","volume":"88","author":"RM","year":"1998","journal-title":"Am J Public Health"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/03602532.2019.1620763","article-title":"Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects","volume":"51","author":"Costa","year":"2019","journal-title":"Drug Metab Rev"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/WNL.34.8.1092","article-title":"Bupropion in Parkinson's disease","volume":"34","author":"Goetz","year":"1984","journal-title":"Neurology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0885-3924(97)00176-0","article-title":"Chronic pain in the setting of Parkinson's disease and depression","volume":"14","author":"Stein","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2710.2008.00952.x","article-title":"Treatment of panic disorder with bupropion in a patient with Parkinson's disease","volume":"33","author":"Gebhardt","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1041610210001687","article-title":"Bupropion in the treatment of depression in Parkinson's disease","volume":"23","author":"Zaluska","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0037-1601887","article-title":"Impulse control disorders and related complications of Parkinson's disease therapy","volume":"37","author":"Lopez","year":"2017","journal-title":"Semin Neurol"},{"key":"R26-20250504","article-title":"Dopamine agonists and impulse control disorders in Parkinson's disease","volume":"09","author":"Wylie","year":"2013","journal-title":"US Neurol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","article-title":"ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease","volume":"88","author":"Antonini","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jns.2011.05.044","article-title":"Impulsive and compulsive behaviors in Parkinson's disease: a one-year follow-up study","volume":"310","author":"Avila","year":"2011","journal-title":"J Neurol Sci"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different generations of type-b monoamine oxidase inhibitors in Parkinson's disease: from bench to bedside","volume":"17","author":"Alborghetti","year":"2019","journal-title":"Curr Neuropharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:13:18Z","timestamp":1746339198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024568"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024568","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"2020-11-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}